Phase II Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Recurrent Glioblastoma

Trial Profile

Phase II Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Recurrent Glioblastoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Nov 2017

At a glance

  • Drugs Dianhydrogalactitol (Primary) ; Lomustine
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Sponsors Del Mar Pharmaceuticals
  • Most Recent Events

    • 21 Nov 2017 According to a DelMar Pharmaceuticals media release, interim results from the study have been presented at the 22nd Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO).
    • 21 Nov 2017 Interim results published in a DelMar Pharmaceuticals media release.
    • 06 Sep 2017 According to a DelMar Pharmaceuticals media release, update from the study will be presented at the 19th Annual Rodman & Renshaw Global Investment Conference 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top